Claims for Patent: 11,690,854

Summary for Patent: 11,690,854

Title:	Methods of treating heavy menstrual bleeding
Abstract:	The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.
Inventor(s):	Juki Wing-Keung Ng, Mohamad Shebley
Assignee:	AbbVie Inc
Application Number:	US17/047,871
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,690,854
Patent Claims:	1. A method of managing moderate to severe pain associated with endometriosis in a premenopausal adult human female patient suffering from endometriosis and having hepatic impairment classified as Child-Pugh B, the method comprising: providing a tablet comprising 155.2 mg or 207.0 mg of a sodium salt of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid (“elagolix sodium”), measuring hepatic function of the patient and determining that the patient has hepatic impairment classified as Child-Pugh B, orally administering the tablet comprising 155.2 mg of elagolix sodium to said patient having hepatic impairment classified as Child-Pugh B once daily for up to 6 months; wherein said method manages the moderate to severe pain associated with endometriosis in the patient. 2. A method of managing moderate to severe pain associated with endometriosis in a premenopausal adult human female patient suffering from endometriosis and having hepatic impairment classified as Child-Pugh B, the method comprising: oral administration of a tablet comprising 155.2 mg of a sodium salt of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid (“elagolix sodium”) to the patient having hepatic impairment classified as Child-Pugh B, and continuing said oral administration to the patient having hepatic impairment classified as Child-Pugh B once daily for up to 6 months; wherein said method manages the moderate to severe pain associated with endometriosis in the patient.